NASDAQ
Apellis Pharmaceuticals, Inc. (APLS) reported revenue of $1.00B and net income of $22.39M for FY 2025. The gross profit margin is 89.8% with a net profit margin of 2.2%.
Financial data for APLS
28.46% YoY
111.31% YoY
111.25% YoY
Annual Income Statement for APLS
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $1B | $781M | $397M | $75M | $67M |
| Cost of Revenue | $102M | $118M | $59M | $6M | $5M |
| Gross Profit | $902M | $664M | $338M | $70M | $61M |
| Operating Expenses | $846M | $829M | $855M | $664M | $598M |
| Operating Income | $55M | -$165M | -$517M | -$595M | -$536M |
| Net Income | $22M | -$198M | -$529M | -$652M | -$746M |
| EPS | $0.18 | $-1.60 | $-4.45 | $-6.15 | $-8.84 |
| EBITDA | $70M | -$155M | -$495M | -$617M | -$731M |
No price data available for this timeframe.